McMaster University engineers have devised a way to make testing for new drugs more efficient and affordable, and reduce the time for helpful medications to reach the public
Chemical Engineering Associate Professor Todd Hoare and Rabia Mateen, a PhD candidate in Biomedical Engineering, have created a printed paper-based device that can speed up and improve the accuracy of the drug screening process. Their work, which could also be used to diagnose diseases, identify environmental contaminants and pinpoint biological warfare agents, was published in Nature Communications in February.
Currently, drug testing is done in multiple stages, with the first stage involving testing thousands of drug candidates in rapid succession to see how well they bind, block or degrade a molecule of interest to the target disease. Subsequent stages involve more extensive testing of drugs that show promise in this first step.
However, the way this initial first screen is now done results in many inaccurate results, with as many as 95% of drug candidates having no chance of becoming a useful drug. In most cases, these inaccuracies arise from the candidate drugs sticking together during the screen to create particles that physically, instead of chemically, block the activity of the molecule targeted by the drug. Such inaccuracies are only now discovered in the slower and more expensive second stage of screening, resulting in significant time and money wasted during the drug discovery process.
Hoare and Mateen have come up with a way to improve the first stage of testing by using a new printable hydrogel, a network of polymers used in everything from contact lenses to disposable diapers. The thin layers of printed hydrogels can form a cage around the target molecule so drug particles formed can’t access the target molecule and trigger the inaccurate result. Instead, only drugs that chemically bind to the target molecule (the ones that could become practical drugs) are allowed into the hydrogel to give a positive result. The printed device developed is inexpensive and can be used directly in drug screening, improving accuracy without requiring a significant change in how drug screening is now done. As an added benefit, the same sensitivity can be achieved using much less sample volume, further reducing the cost of the screen.
“We had already developed the printing method, but were not sure what to do with the materials,” Mateen said. “Reading about this significant issue in the area of drug screening made me realize that these materials could directly address this problem in a simple and effective way.”
The researchers expect this to make testing more affordable and to speed up the discovery of new drugs. In addition, to help address the surge of antibiotic resistance, the technology can also help to more quickly identify “helper drugs” that can make even drug-resistant bacteria susceptible to our current antibiotics.
“As the next step, we are looking for industry partners to prove the effectiveness of our technology on a full-scale screen of thousands of molecules that can help to extend the lifetime of our current antibiotics,” Hoare said. “We are optimistic this approach can help to bring new effective drugs to patients faster than is currently possible”.
Learn more: McMaster University engineers make drug testing more efficient and affordable
The Latest on: Drug discovery
[google_news title=”” keyword=”Drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug discovery
- Bloodsucking fly behind ‘new drug discovery’on May 1, 2024 at 12:11 am
Researchers at the University of Sydney have discovered a potentially “game-changing” new drug capable of preventing blood clots and fatal bleeding during surgery – thanks to the bloodsucking African ...
- NYC-based AI drug discovery company moves HQ to Cambridgeon April 30, 2024 at 6:57 am
If you are not in Boston, you are not in biotech, in my opinion,” said the founder of Insilico, a 10-year-old AI drug discovery company that's moving its headquarters from New York to Massachusetts.
- Xaira Launches with $1 Billion to Pioneer AI-Driven Drug Discoveryon April 28, 2024 at 11:36 pm
Xaira Therapeutics, an AI drug discovery startup, recently launched with a remarkable $1 billion funding, backed by prominent investors like ARCH Venture Partners and Foresite Labs. The company, led ...
- A Pharmaceutical Company is Working to Speed Up the Drug Development Process with AIon April 28, 2024 at 9:50 pm
Algorae Pharmaceuticals is finding ways to revamp its process of drug development from cost saving and speed to timeline of drug research and delivery by ...
- Drug Discovery Services Market To Reach USD 75.3 Billion By 2032, Says DataHorizzon Researchon April 27, 2024 at 6:31 am
The drug discovery services market size was valued at USD 20.8 Billion in 2023 and is expected to reach a market size of USD 75.3 Billion by 2032 at a CAGR of 15.4%.Fort Collins, Colorado, April 27, ...
- This Biotech Startup Aims To Speed Up Drug Testing On Animalson April 26, 2024 at 3:29 am
Gordian Biotechnology’s platform allows for potentially hundreds of gene therapies to be tested in an animal at the same time — without harming it.
- Using Explainable AI To Ensure Drug Discovery Safetyon April 25, 2024 at 5:00 pm
Can you discuss the significance of this for drug discovery/ development? SW: Safety is a huge cause of failure, 56% of projects are failing from preclinical trials onwards due to safety. Yet, when we ...
- A shortcut for drug discovery: Novel method predicts on a large scale how small molecules interact with proteinson April 25, 2024 at 11:00 am
For most human proteins, there are no small molecules known to bind them chemically (so-called "ligands"). Ligands frequently represent important starting points for drug development but this ...
- The Difference Is the Data: Drug Discovery’s AI Revolutionon April 25, 2024 at 4:00 am
New data-intensive platforms continue to leverage artificial intelligence tools for improved speed and failure rate reductions for drug discovery.
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugson April 24, 2024 at 9:19 pm
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture ...
via Bing News